Vical Incorporated - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
VICL Nasdaq 2836 http://www.vical.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vical Incorporated

Does Vical Incorporated’s (NASDAQ:VICL) Past Performance Indicate A Weaker Future? - May 15th, 2018 6:35 pm
Edited Transcript of VICL earnings conference call or presentation 3-May-18 4:00pm GMT - May 8th, 2018 5:43 pm
Vical: 1Q Earnings Snapshot - May 3rd, 2018 4:39 am
Vical Reports First Quarter 2018 Financial and Operational Results - May 3rd, 2018 4:30 am
Market Trends Toward New Normal in City Office REIT, Malibu Boats, Vical, Renasant, Genocea Biosciences, and Lindsay — Emerging Consolidated Expectations, Analyst Ratings - May 2nd, 2018 5:45 am
Vical Announces News Release and Conference Call Schedule for First Quarter 2018 Financial Results - Apr 26th, 2018 2:05 pm
Analysis: Positioning to Benefit within ICF International, Invitae, Encore Wire, Alexandria Real Estate Equities, Syndax Pharmaceuticals, and Vical — Research Highlights Growth, Revenue, and Consolidated Results - Mar 19th, 2018 6:00 am
Edited Transcript of VICL earnings conference call or presentation 15-Mar-18 4:00pm GMT - Mar 15th, 2018 9:11 pm
Vical Incorporated to Host Earnings Call - Mar 15th, 2018 7:00 am
Vical reports 4Q loss - Mar 15th, 2018 4:47 am
Vical Reports Fourth Quarter 2017 Financial and Operational Results - Mar 15th, 2018 4:30 am
Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2017 Financial Results - Mar 8th, 2018 7:07 pm
A Deeper Look at Atara Biotherapeutics’ ATA129, ATA520, and ATA230 - Feb 1st, 2018 5:34 am
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group - Jan 29th, 2018 8:17 am
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients - Jan 22nd, 2018 1:00 am